A Randomized, Open-label, Multi-center Phase II Study to Compare Bevacizumab Plus Sorafenib Versus Sorafenib for the Third-line Treatment of Patients With Metastatic Renal Cell Carcinoma
Phase of Trial: Phase II
Latest Information Update: 12 May 2017
At a glance
- Drugs Bevacizumab (Primary) ; Sorafenib (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 07 May 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 07 May 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
- 02 Jun 2015 Interim results (n=33) presented at the 51st Annual Meeting of the American Society of Clinical Oncology.